Home

Ligand Pharmaceuticals Incorporated - Common Stock (LGND)

124.98
+0.00 (0.00%)
NASDAQ · Last Trade: Jul 11th, 5:54 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Pelthos, Ligand Gain After Launch Of First Prescription-At-Home Treatment For Water Wartsstocktwits.com
The launch triggered a $5 million milestone payment to Ligand, which also holds a 56% stake in Pelthos and is eligible for royalties and additional commercial milestones.
Via Stocktwits · July 10, 2025
Pelthos Therapeutics Launches First At-Home Prescription Gel For Highly Contagious Skin Diseasebenzinga.com
Pelthos launches Zelsuvmi, the first FDA-approved at-home prescription gel for molluscum, shown to clear lesions in as little as two weeks.
Via Benzinga · July 10, 2025
Verona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesdaybenzinga.com
Via Benzinga · July 9, 2025
Earnings Scheduled For May 8, 2025benzinga.com
Via Benzinga · May 8, 2025
Gold Falls Over 1%; D.R. Horton Posts Downbeat Earningsbenzinga.com
Via Benzinga · April 17, 2025
Earnings Scheduled For February 27, 2025benzinga.com
Via Benzinga · February 27, 2025
Demystifying Ligand Pharmaceuticals: Insights From 10 Analyst Reviewsbenzinga.com
Via Benzinga · December 11, 2024
A Closer Look at 7 Analyst Recommendations For Ligand Pharmaceuticalsbenzinga.com
Via Benzinga · November 8, 2024
Channel Therapeutics Stock Soars On Announcement Of Subsidiary’s Merger With Ligand Pharma Units: Retail’s Elatedstocktwits.com
Under the agreement, Ligand’s wholly owned subsidiaries, Pelthos Therapeutics Inc. and LNHC, Inc. will combine with CHRO Merger Sub Inc., a wholly-owned subsidiary of Channel.
Via Stocktwits · April 17, 2025
Dow Falls Over 1%; US Initial Jobless Claims Declinebenzinga.com
Via Benzinga · April 17, 2025
EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entitybenzinga.com
Ligand and Channel Therapeutics to merge in $50 million deal to launch Zelsuvmi for molluscum and advance NaV 1.7 chronic pain programs.
Via Benzinga · April 17, 2025
Analyst Sees Big Upside In Ligand's Capital-Efficient Biotech Strategybenzinga.com
Ligand earns Buy rating from Stifel for its royalty-based funding model and biotech partnerships amid strong revenue and earnings growth.
Via Benzinga · April 10, 2025
Assessing Ligand Pharmaceuticals: Insights From 7 Financial Analystsbenzinga.com
Via Benzinga · October 21, 2024
The Latest Analyst Ratings For Ligand Pharmaceuticalsbenzinga.com
Via Benzinga · October 3, 2024
Looking Into Ligand Pharmaceuticals's Recent Short Interestbenzinga.com
Via Benzinga · August 16, 2024
Assessing Ligand Pharmaceuticals: Insights From 6 Financial Analystsbenzinga.com
Via Benzinga · July 30, 2024
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursdaybenzinga.com
Via Benzinga · April 10, 2025
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.investors.com
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.
Via Investor's Business Daily · January 9, 2025
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.investors.com
The companies held competing events on Sunday to discuss their multiple myeloma treatments.
Via Investor's Business Daily · December 9, 2024
Critical Insights From Ligand Pharmaceuticals Analyst Ratings: What You Need To Knowbenzinga.com
Via Benzinga · October 21, 2024
What 4 Analyst Ratings Have To Say About Ligand Pharmaceuticalsbenzinga.com
Via Benzinga · June 28, 2024
Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Reviewinvestors.com
After Monday's panicked global sell-off, markets have calmed down.
Via Investor's Business Daily · August 9, 2024
LGND Stock Earnings: Ligand Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024investorplace.com
LGND stock results show that Ligand Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 6, 2024
Halozyme And Ligand — Two Leading Biotechs — Smash Quarterly Forecastsinvestors.com
Halozyme and Ligand beat second-quarter expectations late Tuesday. But only one of the biotech stocks jumped.
Via Investor's Business Daily · August 6, 2024
3 Magnificent Growth Stocks to Buy Hand Over Fistfool.com
Small-cap stocks could get a boost from the central bank's anticipated rate cuts in 2025. These three stocks may be a great way to get ahead of this catalyst.
Via The Motley Fool · May 22, 2024